At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer
In Brief
A Phase 4 clinical trial evaluating Long DOAC and Short DOAC for Venous Thrombosis and 2 related conditions. Completed, enrolled 179 participants across 1 site.
Detailed Summary
The primary purpose of this study is to determine the optimal duration of anticoagulation therapy (6 months versus 18 months) with direct oral anticoagulant (DOAC) for cancer-associated low-risk pulmonary embolism patients. The major secondary purpose of this study is to investigate whether home treatment of cancer-associated low-risk pulmonary embolism patients with rivaroxaban is feasible, effective, and safe through an observational management study.
Study Details
Timeline
Interventions
Administration of Rivaroxaban for 18 months
Administration of Rivaroxaban for 6 months